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ending culture results, and 30% of antimicrobial prescribing was
ot changed. After one year, the respective percentages were:
0%, 20%, and 30%. Incorporating educational conferences into the
rogram, decreased cases requiring review somewhat. However,
eriodic increases related to housestaff rotations and medical staff
hanges were noted. Coordination with microbiology laboratory,
ospital infection control, and quality assurance groups aided in
ompliance with guidelines. During the initial year, DOT per 1000
atient-days decreased by 36% for targeted antibiotics with a cost-
avings of $277,000 (30% of total antimicrobial budget).
Conclusion: A hospital antimicrobial SP can use EMR to rapidly
ather information from multiple areas allowing assessment of
ppropriate antimicrobial use. Currently plans are to expand the
ducational portion of the program and institute point-of-service
eedback via CPOE. It is hoped that assessment of program effec-
iveness can be improved and impact on the hospital antibiogram
etermined. Hospitals considering antimicrobial stewardship pro-
rams and/or implementing an EMR can take advantage of many
f our ﬁndings.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.632
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valuation of vancomycin dosing in overweight and obese
atients with a creatinine clearance less than 60 milliliters per
inute
. Spears ∗, T. Dang, J. Eckert, J. Schmeding
Saint Joseph Hospital, Tampa, Fl, USA
Background: Due to conﬂicting data from pharmacokinetic
tudies in obese patients regarding dosing weight, there is uncer-
aintywhether actual bodyweight is the appropriate dosingweight
o use in this patient population. The goal of this study is to evaluate
hether actual body weight or less than actual body weight (ideal
r adjusted) is a better predictor of the target vancomycin serum
oncentration in overweight and obese patients with a creatinine
learance (CrCl) less than 60 ml/min.
Methods: A vancomycin usage report was used to identify
atients on vancomycin between December 2010 and July 2011.
retrospective chart review using the health system’s electronic
edical record was performed to identify adult patients 18 years
f age or older with a body mass index (BMI) greater than 24.9
g/m2 (overweight) or BMI greater than 29.9 kg/m2(obese) and
rCl less than 60 ml/min, who received vancomycin treatment for
ore than48hours andhadat least one serumvancomycin concen-
ration drawn. The vancomycin dose was reviewed to determine if
ctual body weight or less than actual body weight was used to
alculate the initial dose. Patients whose dosing weight could not
learly be determined to be either actual or less than actual were
xcluded in addition to dialysis or pregnant patients. The percent-
ge of patients who had a serum vancomycin concentration within
he target range for the indicated diagnosis when dosed based on
ctual body weight versus when initially dosed based on less than
ctual body weight was determined.
Results: A total of 83 patients were identiﬁed. Most patients
ere dosed based on less than actual body weight (n =68,82%). Ofhese, 36 (53%) had a therapeutic, 15 (22%), had a subtherapeutic,
nd 17 (25%) had a supratherapeutic vancomycin serum concen-
ration. Of these patients dosed on actual body weight (n =15,18%),fectious Diseases 16S (2012) e317–e473 e445
1 (7%) had a therapeutic, 5 (33%) had a subtherapeutic, and 9 (60%)
had a supratherapeutic vancomycin serum concentration.
Conclusion: Supratherapeutic vancomycin serum concentra-
tions may be preventable when using less than actual body weight
to dose vancomycin in overweight and obese patients with a crea-
tinine clearance less than 60ml/min.
http://dx.doi.org/10.1016/j.ijid.2012.05.633
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Ignorance: a blessing or a curse-awareness among Indian physi-
cians on NDM-1 and its impact on antibiotic selection
D. Sureshkumar1,∗, J. Hemalatha2, A. Ghafur3
1 Apollo Hospital, Chennai, India
2 Infectious Disease Education and Research Foundation, Chennai, TN,
India
3 Apollo Hospitals, Chennai, India
Background: Lack of awareness on the seriousness of antimi-
crobial resistance is an important contributing factor to its global
dissemination. Recent publications on the NDM-1(New Delhi
metallo- betalactamase -1) producing bacteria did indeed create
a stir among the public, medical community and the media. But the
level and depth of awareness among Indian physicians on this new
resistance mechanism is not yet studied. The objective of the study
was to assess physicians’ awareness regarding NDM-1 producing
bacteria and toevaluate their understandingon theantibiotic selec-
tion, in the era of NDM-1.
Methods: The cross-sectional survey was carried out among
physicians afﬁliated to various hospitals in South India, using struc-
tured, anonymous questionnaire (regarding NDM-1 awareness,
preferred antibiotic for hospitalized patients in the current era)
between December 2011 and January 2012.
Results: A total of 114 physicians completed the questionnaire.
Only 29.13% (31/114) of the participants were aware on both the
presence of the new resistance mechanism and its name. One ﬁfth
of the participants (22/114-19.29%)were neither aware of the pres-
ence of a new resistance mechanism in the continent nor know the
name NDM-1. However, majority (61/114 -53.50%) of the partici-
pants were aware about the presence but not the name. Nearly half
of the physicians (15/31) who were aware about NDM-1 preferred
either carbapenemor abetalactam-betalactamse inhibitor (BL-BLI)
combination as empirical therapy for treating sepsis in hospitalised
patients, but physicians who were unaware about the NDM-1, two
(9.09% - 2/22) preferred BL-BLI and none chose carbapenem. Col-
istin or tigecycline was not a choice of any of the participants.
Conclusion: Despite the NDM-1 controversy, half of the partici-
pants haven’t heard the name NDM-1, even though they are aware
of a new resistance mechanism in the Indian subcontinent. One
ﬁfth of the doctors aren’t even aware of this new resistance mech-
anism. None of the participant chose colistin/tigecycline to treat
sepsis in the NDM-1 era. Urgent measures should be undertaken to
educate Indian physicians on basics of antimicrobial resistance andhttp://dx.doi.org/10.1016/j.ijid.2012.05.634
